Hepatitis C in 2011: A new standard of care and the race towards IFN-free therapy

Nature Reviews Gastroenterology and Hepatology

Volumn 9, Issue 2, 2012, Pages 67-68

  Hofmann, Wolf Peter ^a   Zeuzem, Stefan ^b  

^a POLIKUM MVZ GmbH   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; BI 201335; BI 207127; BOCEPREVIR; DACLATASVIR; GS 9256; NONSTRUCTURAL PROTEIN 3; PEGINTERFERON ALPHA; PSI 7977; RIBAVIRIN; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS RNA; VX 222;

ANTIVIRAL ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; HEALTH CARE QUALITY; HEPATITIS C; HUMAN; INFECTION RATE; LOW DRUG DOSE; MONOTHERAPY; PRIORITY JOURNAL; RETREATMENT; REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VIROTHERAPY; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RNA, VIRAL; STANDARD OF CARE;

EID: 84856964947     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2011.249     Document Type: Review

References (10)

1. Poordad, F. et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1195-1206 (2011).
2. Jacobson, I. M. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364, 2405-2416 (2011).
3. Bacon, B. et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1207-1217 (2011).
4. Zeuzem, S. et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364, 2417-2428 (2011).
5. Zeuzem, S. et al. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 141, 2047-2055 (2011).
6. Zeuzem, S. et al. The protease inhibitor GS-9256 and non-nucleoside polymerase inhibitor tegobuvir alone, with RBV or peginterferon plus RBV in hepatitis C. Hepatology http:// dx.doi.org/10.1002/hep.24744.
7. Di Bisceglie, A. et al. VX-222 with TVR alone or in combination with peginterferon alfa2a and ribavirin in treatment-naive patients with chronic hepatitis C: ZENITH study interim results [abstract]. J. Hepatol. 54, S540 (2011).
8. Lok, A. S. et al. Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders [abstract]. J. Hepatol. 54, S536 (2011).
9. Chayama, K. et al. Dual oral combination therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 achieved 90% sustained virologic response (SVR12) in HCV genotype 1b-infected null responder [LB-4]. Hepatology 54 (Suppl. 1), 100A (2011).
10. Gane, E. et al. Once daily PSI-7977 plus RBV: pegylated interferon-ALFA not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3 [abstract 34]. Hepatology 54 (Suppl. 1), 377A (2011).